HMAO-B-IN-9

HMAO-B-IN-9 (Compound 25c) is a non-competitive inhibitor for monoamine oxidase B (MAO-B) with an IC50 of 1.58 µM (hMAO-B) . hMAO-B-IN-9 forms complex with iron ions as a chelator, and inhibits Erastin (HY-15763) -induced ferroptosis. hMAO-B-IN-9 exhibits antioxidant activity by downregulating the level of reactive oxygen species (ROS) . hMAO-B-IN-9 improves cognitive function in mice, without significant toxicity (30 mg/kg) . hMAO-B-IN-9 is blood-brain barrier permeable, according to the in silico prediction[1].

Product Specifications

UNSPSC

12352005

Target

Ferroptosis; Monoamine Oxidase; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/hmao-b-in-9.html

Smiles

FC1=CC(COC2=CC=C(OC=C(CN3C=CC(C(O)=C3C)=O)C4=O)C4=C2)=CC=C1

Molecular Formula

C23H18FNO5

Molecular Weight

407.39

References & Citations

[1]Zou DJ, et al., Chromone-deferiprone hybrids as novel MAO-B inhibitors and iron chelators for the treatment of Alzheimer's disease. Org Biomol Chem. 2024 Jul 31;22 (30) :6189-6197.